PP040—Drug information unit–valuable source of information, novi sad experience  by Vukmirovic, S. et al.
Clinical Therapeutics
e30 Volume 35 Number 8S
Conclusion: LHA tends to accept EU requirements as much as it 
could match local regulation, but local regulation differs significantly 
from EU. As a consequence, LSU makes additional efforts and com-
munications with LHA and Company, to fulfill each requirement 
in its own way. The differences could be overcome with harmo-
nization of local regulation with EU and if LHA receive access to 
EudraVigilance database.
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Introduction: Medical and pharmaceutical professionals in Serbia 
gather information on drugs from the National Agency of Drugs 
and Medical Devices or from the various publications such as British 
National Fromulary and Physicians Drug Reference. General pop-
ulation can obtain information from their general practitioners 
(GP) or pharmacist. At Department of Pharmacology and Clinical 
Pharmacology, Medical faculty of Novi Sad, there exists a Drug 
Information Unit, regional center offering drug information to both 
professional and general population in Vojvodina (~1,600,000 inhab-
itants).
Patients (or Materials) and Methods: Clients require information 
by telephone (> 99.5% request) or by e-mail. Interns in Clinical 
Pharmacology collect necessary data regarding the therapeutic 
problem (eg, age and sex of the patient, other drugs taken, present 
diseases). After case solving, and upon the approval from the senior 
clinical pharmacologist, interns deliver the information to the client 
(both by telephone and e-mail).
Results: About 3% of all requests are from general population (usu-
ally questions on interactions, side effects, dosing, and administra-
tion). Remaining requests are from health (20% from GPs and 80% 
from specialists) or pharmaceutical professionals. Almost 30% of all 
of the requests of the health professional are regarding possible drug–
drug or drug–disease interactions. About 12% of requests are related 
to side effects of the administered drug. Pregnancy and lactation are 
subjects of interest in 15% of overall number of requests. Maximal 
doses allowed and posology have shares of ~11%. Remaining infor-
mation is concerning the pharmacokinetics of the drug, first-line 
drugs for certain disease, dosing in children, etc.
Conclusion: According to our experience, the Drug Information 
Unit is quite useful source of information for both professionals and 
general population offering various information on different topics 
related to drugs.
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Introduction: Our study assessed the safety of low doses of metha-
done combined with benzodiazepines during first month of metha-
done maintenance treatment (MMT) in opioid addicts, according to 
differences in corrected QT (QTc) interval and side effects.
Patients (or Materials) and Methods: The study included patients 
with a diagnosis of opioid dependence, who were referred to the 
MMT at the Clinic of Psychiatry, Clinical Centre of Vojvodina, Novi 
Sad, during 2012. All patients were interviewed about their age, 
duration of heroin misuse, and the presence of ECG disorders in the 
first-degree relatives. One month after the beginning of MMT, they 
were interviewed about experienced side effects. Data about applied 
methadone dose and the use of benzodiazepines were collected from 
the medical history of each patient. Before the methadone intake for 
the first time and 1 month after the beginning of MMT, all patients 
underwent a 12-lead ECG. The QTc was calculated using Bazett’s 
formula.
Results: A total of 20 patients were enrolled in the study during the 
observed period. Their average age (SD) was 32.21 (5.63) years. 
The average heroin misuse time (SD) was 11.95 (4.02) years. In the 
patients’ history, no cardiovascular diseases were reported, as well as 
sudden cardiac death or family history of long QTc in the first-degree 
relatives. A statistically significant increase (P < 0.05) in the length 
of QTc intervals measured after 1 month of MMT (QTc1) in com-
parison with those at the baseline (QTc0) was observed. The mean 
(SD) methadone dose was 45.26 (15.41) mg. The most frequently 
used drug in combination with methadone was diazepam, which 
was used in 85% of patients. The mean dose (SD) of diazepam was 
30.93 (10.36) mg. A statistically significant dose-dependent correla-
tion between concomitantly used diazepam daily dose and QTc1 
(R2 = 0.47, P = 0.008) was revealed, but without a statistically sig-
nificant dose-dependent correlation between methadone and QTc1 
(P = 0.960). The most commonly reported side effects were sweating 
(65%), obstipation (60%), and itch (55%). None of participants 
experienced any cardiac side effects.
Conclusion: With respect to the results, it would be advisable to 
perform both pretreatment and regular ECG checkup after 1 month 
of MMT, especially in case of concomitant use of benzodiazepines.
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Introduction: According to the recommendations of the World 
Health Organization, ergot alkaloids are neither the drug of first 
choice for the induction of the labor and not for the treatment of the 
postpartum hemorrhage because of their harmful side effects. The 
objective of this research was to follow the influence of the educa-
